Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05418244 · ClinicalTrials.gov registry record · Phase 2
Inhaled Isopropyl Alcohol for Treatment of Nausea
A Phase 2 study of Nausea and Vomiting, sponsored by State University of New York at Buffalo.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
- 1
- Study location
NCT05418244: Recruiting Phase 2 study of Nausea and Vomiting, sponsored by State University of New York at Buffalo.
NCT05418244 is a Phase 2 study of Nausea and Vomiting that is actively recruiting participants, run by State University of New York at Buffalo. The registered enrollment target is 84 participants, below the 239-participant average among 17 other Nausea trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05418244, a Phase 2 study of Nausea and Vomiting, is actively recruiting participants, sponsored by State University of New York at Buffalo.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine the efficacy of inhaled isopropyl alcohol in treating nausea/vomiting among pediatric patients compared with the conventional ondansetron, or placebo treatment in a tertiary care pediatric emergency department.
Primary Outcome
Baxter Animated Retching Faces nausea score, 0-10 with higher score meaning worse nausea
Conditions Studied
Interventions
- OTHER Inhaled Isopropyl Alcohol
- DRUG Oral Ondansetron
- OTHER Inhaled Placebo
Study Locations (1)
New York
- Oishei Children's Hospital - Buffalo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2022-04-20 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 2 |
What NCT05418244 shows while recruiting
NCT05418244 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 84 participants, a relatively small participant target, below the 239-participant average among 17 other Nausea trials with a reported enrollment target (65% lower).
The record links to 3 conditions, with Nausea appearing as the primary indexed condition, and to 3 interventions - of which Inhaled Isopropyl Alcohol is the first listed.
NCT05418244 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05418244 about?
NCT05418244 is a clinical study titled "Inhaled Isopropyl Alcohol for Treatment of Nausea". To determine the efficacy of inhaled isopropyl alcohol in treating nausea/vomiting among pediatric patients compared with the conventional ondansetron, or placebo treatment in a tertiary care pediatric emergency department.
What is the current status of trial NCT05418244?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2022-04-20. Estimated completion is 2026-06-30.
What conditions does trial NCT05418244 study?
This clinical trial studies the following conditions: Nausea, Vomiting, Children, Only.
What interventions are being tested in trial NCT05418244?
The interventions under investigation include: Inhaled Isopropyl Alcohol (OTHER), Oral Ondansetron (DRUG), Inhaled Placebo (OTHER).
Who is sponsoring clinical trial NCT05418244?
This trial is sponsored by State University of New York at Buffalo, which has 243 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05418244 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nausea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05418244's enrollment target sits among peer trials
84 12th of 17 higher than 6 of 17 other Nausea trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Nausea trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Antiemetic Fosaprepitant To Remedy Nausea and Vomiting
RECRUITING · Phase 2
-
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
RECRUITING · Phase 2
-
RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy
RECRUITING · Phase 2
-
Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With Cancer
COMPLETED · Phase 2
-
Alternate Nostril Breathing (ANB) for 1st Trimester Nausea and Vomiting
RECRUITING · NA
-
Chronic Nausea and Vomiting in Patients With Normal Gastric Emptying Using the Enterra® Therapy System (NAVIGATE)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02391519 · 84 participants
Effects of High Altitude on AMPK Activation
- NCT03838536 · 84 participants · NA
Synergistic Activity of Human Milk Nutrients and Infant Cognition
- NCT03884075 · 84 participants · Phase 2
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- NCT03894917 · 84 participants
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI